Blog

FDA published a warning on the risks of testosterone therapy1. This warning prompted news organizations to cover stories about these new risks, and now prominent consumer productions agencies are calling for changes to the warning labels of testosterone therapy products2.

Earlier this year, a group of private companies and institutions released a new mobile application in collaboration with the Food and Drug Administration Center for Devices and Radiologic Health.

After over 1000 adverse event reports, several consumer watchdog groups have urged diabetics to avoid using Actos or its generic equivalent. Many have espoused that actos use may not be worth the associated health risks. A group by the name of “Consumer Reports” noted that Actos should only be used as a “last resort” diabetes drug.

According to a recent review of FDA adverse event reports, the FDA has received over 1000 reports from individuals reporting unexplained diagnoses of bladder cancer after Actos use. This comes after several prominent scientific reports linked Actos use to an increased likelihood of developing bladder cancer.

A recent request was filed to centralize all New Jersey State Court Stryker Hip Implant claims in front of one judge for joint discovery and handling. Cases are often centralized to save litigation resources and expedite the overall litigation process. If approved, this request for centralization may be the first step in a potential MDL, multi-district litigation, for Stryker Hip Implant cases which would include not only New Jersey cases but also include cases throughout the nation.

Stryker Orthopaedics recalled its Rejuvenate hip system and ABG II modular-neck stems, both of which are popular components of many of its most popular hip implant systems. Both the Rejuvenate and ABG II modular-neck stems may be used with either metal or ceramic hip implants.

After being sued by over 600 women who claim that their transvaginal mesh products caused serious-life altering injuries, Johnson & Johnson’s Ethicon unit has decided to stop selling four of its most popular transvaginal mesh products and restrict the usage of other Gynecare mesh products.

According to a new study published in the British Medicine Journal which compared healthy people with patients diagnosed with bladder cancer, Actos use has been associated with an 83% increased risk of bladder cancer and a 200% increased risk of bladder cancer if Actos is used for more than 2 years.

MDL Consolidation to eliminate duplicative discovery, prevent inconsistent pretrial rulings, and conserve the resources of the parties, their counsel and the judiciary

FDA Panel Recommends Label Changes to Reduce Risk of Problems from Fosamax